{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:48:06Z","timestamp":1790534886861,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Matrix Biology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.matbio.2017.12.013","type":"journal-article","created":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T02:42:10Z","timestamp":1514601730000},"page":"318-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Renal fibrosis: Recent translational aspects"],"prefix":"10.1016","volume":"68-69","author":[{"given":"H\u00e9l\u00e8ne","family":"Fran\u00e7ois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Chatziantoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.matbio.2017.12.013_bb0005","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0046-8177(70)80061-2","article-title":"Structural-functional correlations in renal disease. II. The correlations","volume":"1","author":"Schainuck","year":"1970","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2613.2011.00760.x","article-title":"The role of cell plasticity in progression and reversal of renal fibrosis","volume":"92","author":"Dussaule","year":"2011","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM199807093390202","article-title":"Reversal of lesions of diabetic nephropathy after pancreas transplantation","volume":"339","author":"Fioretto","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.matbio.2017.12.013_bb0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cyto.2016.08.019","article-title":"The cellular and signalling alterations conducted by TGF-\u03b2 contributing to renal fibrosis","volume":"88","author":"Vega","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.matbio.2017.12.013_bb0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.ackd.2016.11.002","article-title":"Treatment of renal fibrosis-turning challenges into opportunities","volume":"24","author":"Klinkhammer","year":"2017","journal-title":"Adv. Chronic Kidney Dis."},{"key":"10.1016\/j.matbio.2017.12.013_bb0035","article-title":"A Phase 2, double-blind, Randomized study of fresolimumab or placebo in patients with steroid-resistant primary focal segmental glomerulosclerosis. ASN Kidney Week; 2015; San Diego, CA","author":"Tumlin","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0040","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1172\/JCI200112367","article-title":"Apoptosis in podocytes induced by TGF-beta and Smad7","volume":"108","author":"Schiffer","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.matbio.2017.12.013_bb0045","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.01050207","article-title":"Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis","volume":"2","author":"Cho","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/13543780903501539","article-title":"Pirfenidone: an anti-fibrotic therapy for progressive kidney disease","volume":"19","author":"Cho","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.matbio.2017.12.013_bb0055","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1681\/ASN.2010101049","article-title":"Pirfenidone for diabetic nephropathy","volume":"22","author":"Sharma","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0060","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2016121351","article-title":"Blocking TGF-\u03b2 and \u03b2-catenin epithelial crosstalk exacerbates CKD","author":"Nlandu-Khodo","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0065","doi-asserted-by":"crossref","first-page":"506041","DOI":"10.1155\/2015\/506041","article-title":"TGF-beta blockade increases renal inflammation caused by the C-terminal module of the CCN2","volume":"2015","author":"Rodrigues-D\u00edez","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.matbio.2017.12.013_bb0070","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nrneph.2014.184","article-title":"Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease","volume":"10","author":"Kok","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0075","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2215\/CJN.09321209","article-title":"Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria","volume":"5","author":"Adler","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0080","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1432-2277.2008.00705.x","article-title":"A role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury","volume":"21","author":"Fernandes Bertocchi","year":"2008","journal-title":"Transpl. Int. Off. J. Eur. Soc. Organ Transplant."},{"key":"10.1016\/j.matbio.2017.12.013_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166272","article-title":"Galectin-3 blockade reduces renal fibrosis in two normotensive experimental models of renal damage","volume":"11","author":"Martinez-Martinez","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.matbio.2017.12.013_bb0090","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","article-title":"Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis","volume":"172","author":"Henderson","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0095","doi-asserted-by":"crossref","first-page":"F500","DOI":"10.1152\/ajprenal.00461.2014","article-title":"Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy","volume":"308","author":"Frenay","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0100","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/j.1523-1755.2000.00366.x","article-title":"Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats","volume":"58","author":"Tsuchiyama","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.matbio.2017.12.013_bb0105","doi-asserted-by":"crossref","first-page":"F245","DOI":"10.1152\/ajprenal.00326.2010","article-title":"Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis","volume":"300","author":"Okamura","year":"2011","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0110","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/path.2536","article-title":"Advanced lipoxidation end-products mediate lipid-induced glomerular injury: role of receptor-mediated mechanisms","volume":"218","author":"Iacobini","year":"2009","journal-title":"J. Pathol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.autrev.2016.09.023","article-title":"Role of galectin-3 in autoimmune and non-autoimmune nephropathies","volume":"16","author":"Saccon","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.matbio.2017.12.013_bb0120","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1681\/ASN.2005121256","article-title":"The endothelin system and its antagonism in chronic kidney disease","volume":"17","author":"Dhaun","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0125","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/ncpneph0891","article-title":"Reversal of proteinuric renal disease and the emerging role of endothelin","volume":"4","author":"Barton","year":"2008","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0130","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","article-title":"The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigators","volume":"338","author":"Krum","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.matbio.2017.12.013_bb0135","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1524-6175.2007.07244.x","article-title":"Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study","volume":"9","author":"Black","year":"2007","journal-title":"J. Clin. Hypertens. Greenwich Conn."},{"key":"10.1016\/j.matbio.2017.12.013_bb0140","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/13543784.2017.1325872","article-title":"Atrasentan for the treatment of diabetic nephropathy","volume":"26","author":"Egido","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.matbio.2017.12.013_bb0145","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.matbio.2017.12.013_bb0150","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.matbio.2017.12.013_bb0155","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/0002-9149(82)90390-3","article-title":"Increase in plasma aldosterone during prolonged captopril treatment","volume":"49","author":"Lijnen","year":"1982","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0160","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","article-title":"Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis","volume":"37","author":"Hou","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.matbio.2017.12.013_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007004.pub3","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.matbio.2017.12.013_bb0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"AMETHYST-DN investigators, effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.matbio.2017.12.013_bb0175","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.kint.2016.04.019","article-title":"Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors","volume":"90","author":"Weir","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.matbio.2017.12.013_bb0180","article-title":"The role of cannabinoid receptors in renal diseases","author":"Fran\u00e7ois","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.matbio.2017.12.013_bb0185","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.283.5400.401","article-title":"Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice","volume":"283","author":"Ledent","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.matbio.2017.12.013_bb0190","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/sj.ki.5002540","article-title":"Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats","volume":"72","author":"Janiak","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.matbio.2017.12.013_bb0195","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1210\/en.2011-1423","article-title":"Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db\/db mice","volume":"153","author":"Nam","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.matbio.2017.12.013_bb0200","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/eurheartj\/ehn076","article-title":"Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe study \u2020","volume":"29","author":"Van Gaal","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.matbio.2017.12.013_bb0205","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2012.07.002","article-title":"Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance","volume":"16","author":"Tam","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.matbio.2017.12.013_bb0210","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1515\/jbcpp-2015-0055","article-title":"The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases","volume":"27","author":"Tam","year":"2016","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0215","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ki.2015.63","article-title":"Cannabinoid receptor 1 is a major mediator of renal fibrosis","volume":"88","author":"Lecru","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.matbio.2017.12.013_bb0220","doi-asserted-by":"crossref","first-page":"E5420","DOI":"10.1073\/pnas.1419901111","article-title":"Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy","volume":"111","author":"Jourdan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.matbio.2017.12.013_bb0225","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2337\/db09-1336","article-title":"Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy","volume":"59","author":"Barutta","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.matbio.2017.12.013_bb0230","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.2337\/db10-1809","article-title":"Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy","volume":"60","author":"Barutta","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.matbio.2017.12.013_bb0235","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ki.2014.165","article-title":"Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice","volume":"86","author":"Barutta","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.matbio.2017.12.013_bb0240","first-page":"1655","article-title":"Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy","volume":"32","author":"Barutta","year":"2017","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"key":"10.1016\/j.matbio.2017.12.013_bb0245","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2016101085","article-title":"Proximal tubular Cannabinoid-1 receptor regulates obesity-induced CKD","author":"Udi","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0250","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.matbio.2016.11.009","article-title":"Discoidin domain receptor 1 kinase activity is required for regulating collagen IV synthesis","volume":"57\u201358","author":"Borza","year":"2017","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0255","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fmed.2017.00052","article-title":"Periostin and discoidin domain receptor 1: new biomarkers or targets for therapy of renal disease","volume":"4","author":"Prakoura","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.matbio.2017.12.013_bb0260","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1681\/ASN.2006060677","article-title":"Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease","volume":"17","author":"Flamant","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0265","first-page":"4079","article-title":"Genetic inhibition of discoidin domain receptor 1 protects mice against crescentic glomerulonephritis","volume":"26","author":"Kerroch","year":"2012","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0270","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ajpath.2011.03.023","article-title":"Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy","volume":"179","author":"Guerrot","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0275","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.matbio.2010.03.002","article-title":"Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease","volume":"29","author":"Gross","year":"2010","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0280","doi-asserted-by":"crossref","first-page":"21262","DOI":"10.1038\/srep21262","article-title":"Protective effects of genetic inhibition of discoidin domain receptor 1 in experimental renal disease","volume":"6","author":"Kerroch","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.matbio.2017.12.013_bb0285","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1359\/jbmr.1999.14.7.1239","article-title":"Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta","volume":"14","author":"Horiuchi","year":"1999","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.matbio.2017.12.013_bb0290","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCRESAHA.107.159517","article-title":"Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart","volume":"102","author":"Snider","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.matbio.2017.12.013_bb0295","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/cvr\/cvr067","article-title":"Angiotensin II increases periostin expression via Ras\/p38 MAPK\/CREB and ERK1\/2\/TGF-\u03b21 pathways in cardiac fibroblasts","volume":"91","author":"Li","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.matbio.2017.12.013_bb0300","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1535370216668050","article-title":"Phosphoinositide 3-kinase\/protein kinase B\/periostin mediated platelet-derived growth factor-induced cell proliferation and extracellular matrix production in lupus nephritis","volume":"242","author":"Zhao","year":"2017","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.matbio.2017.12.013_bb0305","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaci.2006.02.046","article-title":"Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals","volume":"118","author":"Takayama","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0310","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jcb.21224","article-title":"Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues","volume":"101","author":"Norris","year":"2007","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.matbio.2017.12.013_bb0315","doi-asserted-by":"crossref","first-page":"13294","DOI":"10.1074\/jbc.M109.088864","article-title":"Interaction between periostin and BMP-1 promotes proteolytic activation of lysyl oxidase","volume":"285","author":"Maruhashi","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.matbio.2017.12.013_bb0320","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1074\/jbc.M109.051961","article-title":"Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture","volume":"285","author":"Kii","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.matbio.2017.12.013_bb0325","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.atherosclerosis.2009.07.046","article-title":"Periostin mediates vascular smooth muscle cell migration through the integrins alphavbeta3 and alphavbeta5 and focal adhesion kinase (FAK) pathway","volume":"208","author":"Li","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.matbio.2017.12.013_bb0330","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2013060664","article-title":"Inhibition of periostin expression protects against the development of renal inflammation and fibrosis","volume":"25","author":"Mael-Ainin","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0335","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1681\/ASN.2016070709","article-title":"NF\u03baB-induced periostin activates integrin-\u03b23 signaling to promote renal injury in GN","volume":"28","author":"Prakoura","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0340","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ajpath.2011.06.002","article-title":"Periostin is induced in glomerular injury and expressed de novo in interstitial renal fibrosis","volume":"179","author":"Sen","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031974","article-title":"Identification of periostin as a critical marker of progression\/reversal of hypertensive nephropathy","volume":"7","author":"Guerrot","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.matbio.2017.12.013_bb0350","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/HJH.0000000000000370","article-title":"Distinct protein signature of hypertension-induced damage in the renal proteome of the two-kidney, one-clip rat model","volume":"33","author":"Vethe","year":"2015","journal-title":"J. Hypertens."},{"key":"10.1016\/j.matbio.2017.12.013_bb0355","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/0961203314566634","article-title":"Periostin: a novel tissue biomarker correlates with chronicity index and renal function in lupus nephritis patients","volume":"24","author":"Wantanasiri","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.matbio.2017.12.013_bb0360","first-page":"2702","article-title":"Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells","volume":"27","author":"Satirapoj","year":"2012","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"key":"10.1016\/j.matbio.2017.12.013_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124055","article-title":"Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus","volume":"10","author":"Satirapoj","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.matbio.2017.12.013_bb0370","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000452228","article-title":"Urinary periostin excretion predicts renal outcome in IgA nephropathy","volume":"44","author":"Hwang","year":"2016","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0375","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/ki.2013.488","article-title":"Periostin promotes renal cyst growth and interstitial fibrosis in polycystic kidney disease","volume":"85","author":"Wallace","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.matbio.2017.12.013_bb0380","doi-asserted-by":"crossref","first-page":"F931","DOI":"10.1152\/ajprenal.00523.2015","article-title":"MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis","volume":"310","author":"Gomez","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0385","doi-asserted-by":"crossref","first-page":"F793","DOI":"10.1152\/ajprenal.00273.2011","article-title":"Identification of a microRNA signature in renal fibrosis: role of miR-21","volume":"301","author":"Zarjou","year":"2011","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0390","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003205","article-title":"MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways","volume":"4","author":"Chau","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.matbio.2017.12.013_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058014","article-title":"Increased circulating miR-21 levels are associated with kidney fibrosis","volume":"8","author":"Glowacki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.matbio.2017.12.013_bb0400","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI75852","article-title":"Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways","volume":"125","author":"Gomez","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.matbio.2017.12.013_bb0405","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1681\/ASN.2013010072","article-title":"MicroRNA-214 antagonism protects against renal fibrosis","volume":"25","author":"Denby","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0410","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1159\/000355721","article-title":"MiR-124 is related to podocytic adhesive capacity damage in STZ-induced uninephrectomized diabetic rats","volume":"37","author":"Li","year":"2013","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.matbio.2017.12.013_bb0415","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.kint.2017.02.012","article-title":"Antagonism of profibrotic microRNA-21 improves outcome of murine chronic renal allograft dysfunction","volume":"92","author":"Schauerte","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.matbio.2017.12.013_bb0420","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1681\/ASN.2015030300","article-title":"MicroRNA-23b targets Ras GTPase-activating protein SH3 domain-binding protein 2 to alleviate fibrosis and albuminuria in diabetic nephropathy","volume":"27","author":"Zhao","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0425","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1681\/ASN.2007070794","article-title":"Inhibition of renal rho kinase attenuates ischemia\/reperfusion-induced injury","volume":"19","author":"Prakash","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0430","first-page":"417","article-title":"Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells","volume":"7","author":"Dolman","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.matbio.2017.12.013_bb0435","doi-asserted-by":"crossref","first-page":"54240","DOI":"10.18632\/oncotarget.11095","article-title":"Interferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis after unilateral ureteral obstruction in mice","volume":"7","author":"Poosti","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.matbio.2017.12.013_bb0440","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2017010013","article-title":"Targeting anti-TGF-\u03b2 therapy to fibrotic kidneys with a dual specificity antibody approach","author":"McGaraughty","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0445","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/1389200218666170116113103","article-title":"Cancer nanotechnology: recent trends and developments in strategies for targeting cancer cells to improve cancer imaging and treatment","volume":"18","author":"Xu","year":"2017","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.matbio.2017.12.013_bb0450","first-page":"w14442","article-title":"Diagnosis and assessment of renal fibrosis: the state of the art","volume":"147","author":"Berchtold","year":"2017","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.matbio.2017.12.013_bb0455","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1681\/ASN.2010111143","article-title":"Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging","volume":"22","author":"Inoue","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0460","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1074\/mcp.M110.001917","article-title":"Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease","volume":"9","author":"Good","year":"2010","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.matbio.2017.12.013_bb0465","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1681\/ASN.2014050423","article-title":"Diagnosis and prediction of CKD progression by assessment of urinary peptides","volume":"26","author":"Schanstra","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0470","first-page":"472","article-title":"Turnover of type III collagen reflects disease severity and is associated with progression and microinflammation in patients with IgA nephropathy","volume":"31","author":"Genovese","year":"2016","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"key":"10.1016\/j.matbio.2017.12.013_bb0475","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2215\/CJN.06610909","article-title":"Urinary procollagen III aminoterminal propeptide (PIIINP): a fibrotest for the nephrologist","volume":"5","author":"Ghoul","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0480","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1681\/ASN.2014070696","article-title":"Urine collagen fragments and CKD progression-the cardiovascular health study","volume":"26","author":"Ix","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175200","article-title":"Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease","volume":"12","author":"Fenton","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.matbio.2017.12.013_bb0490","first-page":"821","article-title":"Circulating levels of periostin may help identify patients with more aggressive colorectal cancer","volume":"34","author":"Ben","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0495","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.alit.2014.07.003","article-title":"Phenotype of asthma related with high serum periostin levels","volume":"64","author":"Matsusaka","year":"2015","journal-title":"Allergol. Int. Off. J. Jpn. Soc. Allergol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0500","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.transproceed.2013.07.069","article-title":"Urine periostin as a biomarker of renal injury in chronic allograft nephropathy","volume":"46","author":"Satirapoj","year":"2014","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.matbio.2017.12.013_bb0505","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2796.2011.02476.x","article-title":"The fibrosis marker galectin-3 and outcome in the general population","volume":"272","author":"de Boer","year":"2012","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.matbio.2017.12.013_bb0510","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.000760","article-title":"Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure","volume":"1","author":"Gopal","year":"2012","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.matbio.2017.12.013_bb0515","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1681\/ASN.2012090909","article-title":"Elevated galectin-3 precedes the development of CKD","volume":"24","author":"O'Seaghdha","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0520","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1681\/ASN.2014010093","article-title":"Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies","volume":"26","author":"Drechsler","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0525","doi-asserted-by":"crossref","first-page":"F514","DOI":"10.1152\/ajprenal.00449.2014","article-title":"Urinary vimentin mRNA as a potential novel biomarker of renal fibrosis","volume":"309","author":"Cao","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0530","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/ki.2011.292","article-title":"Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases","volume":"80","author":"van Balkom","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.matbio.2017.12.013_bb0535","doi-asserted-by":"crossref","first-page":"F1220","DOI":"10.1152\/ajprenal.00148.2013","article-title":"MicroRNA-29c in urinary exosome\/microvesicle as a biomarker of renal fibrosis","volume":"305","author":"Lv","year":"2013","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.matbio.2017.12.013_bb0540","first-page":"1488","article-title":"miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis","volume":"30","author":"Sol\u00e9","year":"2015","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"key":"10.1016\/j.matbio.2017.12.013_bb0545","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1261\/rna.058834.116","article-title":"Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease","volume":"23","author":"Khurana","year":"2017","journal-title":"RNA N. Y. N."}],"container-title":["Matrix Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0945053X17304092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0945053X17304092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T17:40:23Z","timestamp":1570556423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0945053X17304092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":109,"alternative-id":["S0945053X17304092"],"URL":"https:\/\/doi.org\/10.1016\/j.matbio.2017.12.013","relation":{},"ISSN":["0945-053X"],"issn-type":[{"value":"0945-053X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal fibrosis: Recent translational aspects","name":"articletitle","label":"Article Title"},{"value":"Matrix Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.matbio.2017.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}